{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:45:26Z","timestamp":1764859526517,"version":"3.40.5"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Venous thromboembolism (VTE) is a well\u2010known complication in patients with acute lymphoblastic leukaemia (ALL) receiving asparaginase (ASP)\u2010based chemotherapy, including the ASP\u2010intensive Dana\u2010Farber Cancer Institute (DFCI) 91\u201301 protocol for adults. Since 2019, native L\u2010ASP is no longer available in Canada and was replaced by pegylated (PEG)\u2010ASP. To determine whether the incidence of VTE has changed since switching from L\u2010ASP to PEG\u2010ASP, we conducted a single\u2010centred retrospective cohort study. We included 245 adult patients with Philadelphia chromosome negative ALL between 2011 and 2021, with 175 from the L\u2010ASP group (2011\u20132019) and 70 from the PEG\u2010ASP group (2018\u20132021). During Induction, 10.29% (18\/175) of patients who received L\u2010ASP developed VTE, whereas 28.57% (20\/70) of patients who received PEG\u2010ASP developed VTE (<jats:italic>p<\/jats:italic>\u00a0=\u20090.0035; odds ratio [OR] 3.35, 95% confidence interval [CI] 1.51\u20137.39), after adjusting for line type, gender, history of VTE, platelets at diagnosis. Similarly, during Intensification, 13.64% (18\/132) of patients had VTE on L\u2010ASP while 34.37% (11\/32) of patients on PEG\u2010ASP developed VTE (<jats:italic>p<\/jats:italic>\u00a0=\u20090.0096; OR 3.96, 95% CI 1.57\u20139.96 with multivariable analysis). We found that PEG\u2010ASP is associated with a higher incidence of VTE compared to L\u2010ASP, both during Induction and Intensification, despite the administration of prophylactic anticoagulation. Further VTE mitigation strategies are needed in particular for adult patients with ALL receiving PEG\u2010ASP.<\/jats:p>","DOI":"10.1111\/bjh.18683","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T13:34:00Z","timestamp":1676554440000},"page":"645-652","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L\u2010ASP: A retrospective analysis with an ASP\u2010based protocol in adult patients <scp>with acute lymphoblastic leukaemia<\/scp>"],"prefix":"10.1111","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1008-4194","authenticated-orcid":false,"given":"RuiQi","family":"Chen","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-3680","authenticated-orcid":false,"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Seki","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Chan","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-9380","authenticated-orcid":false,"given":"Dawn","family":"Maze","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre C.","family":"Shuh","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Yee","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron D.","family":"Schimmer","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9030-8583","authenticated-orcid":false,"given":"Hassan","family":"Sibai","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12561"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07712.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.229"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.290"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000356"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015511"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11042"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08524.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.23.3077"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239\u2010017\u20101597\u20107"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14671"},{"key":"e_1_2_9_13_1","first-page":"1","article-title":"Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase\u2010based therapy","volume":"2","author":"Sibai H","year":"2020","journal-title":"Br J Haematol"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.2708"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00363-0"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1680839"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2020-0009"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1397661"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010021\u201004252\u2010y"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01877"},{"issue":"46","key":"e_1_2_9_21_1","article-title":"Successful treatment with rivaroxaban of cerebral venous thrombosis and bone marrow necrosis induced by pegaspargase: a case report and literature review","volume":"96","author":"Sui J","year":"2017","journal-title":"Medicine (United States)"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X211013225"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2930-0"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2368-1"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18683","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18683","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T07:58:26Z","timestamp":1718697506000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/bjh.18683"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18683","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"assertion":[{"value":"2022-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}